Piper Sandler Reiterates Overweight on Alnylam Pharmaceuticals (ALNY), 'Confident in AMVUTTRA Approval'
Tweet Send to a Friend
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $304.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
